|
|
| | GSK2894631A Basic information |
| Product Name: | GSK2894631A | | Synonyms: | HPGDS inhibitor 2;GSK2894631A;3-Quinolinecarboxamide, 7-(difluoromethoxy)-N-[trans-4-(1-hydroxy-1-methylethyl)cyclohexyl]-;7-(Difluoromethoxy)- N-[trans-4-(1-hydroxy-1-methylethyl)cyclohexyl]-3-quinolinecarboxamide;HPGDS inhibitor2,PGE synthase,Inhibitor,inhibit,HPGDS inhibitor-2,HPGDS inhibitor 2,Prostaglandin E synthase;GSK-2894631A(HPGDS inhibitor 2);7-(Difluoromethoxy)-N-(trans-4-(2-hydroxypropan-2-yl)cyclohexyl)quinoline-3-carboxamide | | CAS: | 2101626-26-8 | | MF: | C20H24F2N2O3 | | MW: | 378.41 | | EINECS: | | | Product Categories: | | | Mol File: | 2101626-26-8.mol |  |
| | GSK2894631A Chemical Properties |
| Boiling point | 572.5±45.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | 4°C, away from moisture and light | | solubility | DMSO:150.0(Max Conc. mg/mL);396.39(Max Conc. mM) | | pka | 13.22±0.40(Predicted) |
| | GSK2894631A Usage And Synthesis |
| | GSK2894631A Preparation Products And Raw materials |
|